Naltrexone and Buprenorphine Market Size Worth USD 12.40 Billion by 2034 | CAGR: 9.6%

The naltrexone and buprenorphine market size is expected to reach USD 12.40 billion by 2034, according to a new study by Polaris Market Research. The report “Naltrexone and Buprenorphine Market Size, Share, Trends, Industry Analysis Report By Product (Naltrexone, Buprenorphine), By Route of Administration, By Application, By Distribution Channel, By Region– Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Naltrexone and buprenorphine are medications used to treat opioid use disorder by reducing cravings and preventing relapse. There is a shift in how opioid use disorder is being treated from short-term detox to long-term recovery planning. Healthcare professionals now recognize that continued medication support can improve recovery outcomes and lower relapse risks. Naltrexone and buprenorphine are both used in long-term treatment strategies because they help people stay engaged in care and reduce the chance of returning to drug use. As more treatment centers adopt a long-term approach, the need for medications that can be taken safely over time increases. This trend supports continued growth in the use of both medications across various care settings.

Bottom of Form

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below:  https://www.polarismarketresearch.com/industry-analysis/naltrexone-and-buprenorphine-market/request-for-sample

Traditionally, treatment for opioid use disorder was handled mostly by addiction specialists, but this is changing. Now, more primary care providers and general practitioners are offering medication-assisted treatment using naltrexone and buprenorphine. This is partly due to reduced prescribing restrictions and increased training for non-specialists. Patients can now receive treatment from their regular doctors, making it easier to access care. This shift is helping integrate OUD treatment into everyday healthcare, which increases the number of patients who can start and continue treatment. As access widens, use of these medications is expected to keep rising.

Naltrexone and Buprenorphine Market Report Highlights

• In 2024, the buprenorphine segment dominated with a larger share due to its widespread use in managing opioid withdrawal symptoms and reducing cravings.
• The hospitals pharmacies segment is expected to experience significant growth during the forecast period, as hospitals are the first point of care for individuals experiencing overdose or withdrawal.
• In 2024, North America dominated the naltrexone and buprenorphine market with the largest share driven by the high prevalence of opioid use disorder and strong government involvement in expanding access to treatment.
• The Asia Pacific naltrexone and buprenorphine market is experiencing significant growth, due to growing awareness of substance use disorders and efforts to strengthen mental health services.
• A few global key market players are Alkermes, Inc.; Camurus; Collegium Pharmaceutical; Indivior PLC; Orexo US, Inc. (a part of Orexo AB); Sun Pharmaceutical Industries Ltd; and Titan Pharmaceuticals, Inc.

Polaris market research has segmented the naltrexone and buprenorphine market report based on product, route of administration, application, distribution channel, and region:

By Product (Revenue – USD Billion, 2020–2034)

• Naltrexone
• Buprenorphine
  • BELBUCA
  • Sublocade
  • Suboxone
  • Zubsolv
  • Others

By Route of Administration (Revenue – USD Billion, 2020–2034)

• Oral Administration
• Injectable Administration
• Implantable Administration

By Application (Revenue – USD Billion, 2020–2034)

• Opioid Use Disorder (OUD)
• Alcohol Use Disorder (AUD)

By Distribution Channel (Revenue – USD Billion, 2020–2034)

• Hospitals Pharmacies
• Retail Pharmacies
• Others

By Regional Outlook (Revenue – USD Billion, 2020–2034)

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of APAC
• Latin America
  • Argentina
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of MEA